2Wong WM, Gu Q, Chu KM, et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as secondline treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther, 2006, 23:421-427.
3Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17 : 1-12.
4Wang WH, Wong BC, Mukhopadhyay AK, et al. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment Pharmacol Ther, 2000, 14:901-910.
5Sanchez JE, Saenz NG, Rincon MR, et al. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/ dalfopristin and new quinolones. J Antimicrob Chemother, 2000, 46:283-285.
6Xia HH, Yu Wong BC, Talley NJ, et al. Alternative and rescue treatment regimens for Helicobacter pylori eradication. Expert Opin Pharmacother, 2002, 3 : 1301-1311.
7Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy. Dig Liver Dis, 2003, 35:711-715.
8European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut, 1997, 41:8-13.
9Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology, 1998, 115:1272-1277.
10Gisbert JP, Pajares JM. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter, 2005, 10:363-372.
